Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL

J. A. Woyach, A. S. Ruppert, N. A. Heerema, W. Zhao, A. M. Booth, W. Ding, N. L. Bartlett, D. M. Brander, P. M. Barr, K. A. Rogers, S. A. Parikh, S. Coutre, A. Hurria, J. R. Brown, G. Lozanski, J. S. Blachly, H. G. Ozer, B. Major-Elechi, B. Fruth, S. NattamR. A. Larson, H. Erba, M. Litzow, C. Owen, C. Kuzma, J. S. Abramson, R. F. Little, S. E. Smith, R. M. Stone, S. J. Mandrekar, J. C. Byrd

Research output: Contribution to journalArticlepeer-review

763 Scopus citations

Fingerprint

Dive into the research topics of 'Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science